ELISA HIMEL: Open Payments
NPI 1083047427 · HAMMOND, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$851 in 52 payments from 11 companies in 2025. Trend: 2023 $1,032 · 2024 $839 · 2025 $851
Food & beverage: $851
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 27 | $305 |
| Janssen Pharmaceuticals, Inc | 6 | $130 |
| E.R. Squibb & Sons, L.L.C. | 4 | $82 |
| Neurocrine BioSciences, Inc. | 3 | $75 |
| Otsuka America Pharmaceutical, Inc. | 3 | $58 |
| Indivior Inc. | 3 | $56 |
| Vanda Pharmaceuticals Inc. | 1 | $39 |
| Teva Pharmaceuticals USA, Inc. | 2 | $38 |
| Lundbeck LLC | 1 | $27 |
| Braeburn Inc. | 1 | $23 |
Products named: CAPLYTA, INVEGA SUSTENNA, COBENFY, INGREZZA, SUBLOCADE, REXULTI, FANAPT, ABILIFY ASIMTUFII.
Industry payments across LA — which companies pay providers there.
